Jangee (Drospirenone, Ethinylestradiol)

Drospirenone acts as a progestin that suppresses the release of luteinizing hormone and follicle‑stimulating hormone, thereby preventing ovulation. Ethinylestradiol provides estrogenic activity that stabilises the endometrium and thickens cervical mucus, creating an environment that is hostile to sperm and implantation.

The dosing regimen for Jangee is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet following the specific cycle schedule indicated on the prescription label.

Jangee is intended for use only when pregnancy is not desired. It should not be started during pregnancy, and women who become pregnant while taking it should discontinue use and consult their clinician. Safety during breastfeeding has not been fully established; a healthcare provider should assess the risk‑benefit ratio.

To place an order, submit an enquiry on the Jangee product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Jangee contains drospirenone, a progestin with anti‑androgenic and mild diuretic properties, combined with ethinylestradiol. Compared with older progestins, drospirenone may offer benefits such as reduced water retention and potential improvement in acne, while maintaining contraceptive efficacy similar to other combined oral contraceptives.

Jangee tablets should be stored at ambient temperature below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Jangee is taken orally, usually once daily at the same time each day. The tablets are swallowed whole with water and should be taken as directed by the prescribing clinician, following the prescribed cycle regimen.

Serious risks include venous thromboembolism, stroke, myocardial infarction, and severe hypertension. Women with a history of clotting disorders, smoking, or certain cardiovascular conditions should discuss these risks with their healthcare provider before starting Jangee.

Jangee is contraindicated in women with known or suspected pregnancy, active liver disease, uncontrolled hypertension, a history of thromboembolic events, breast cancer, or those who are smokers aged 35 years or older. It should also be avoided in individuals with known hypersensitivity to drospirenone, ethinylestradiol or any tablet excipients.